BMRN
BioMarin Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology · US
$66.35
−0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4B | 3.2B | 2.9B | 2.4B | 2.1B |
| Cost of Revenue | 833.0M | 736.8M | 580.2M | 532.1M | 503.0M |
| Gross Profit | 2.6B | 2.5B | 2.3B | 1.9B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 987.6M | 921.9M | 747.2M | 746.8M | 649.6M |
| SG&A Expense | 1.7B | 1.3B | 1.0B | 892.4M | 823.2M |
| General & Admin Expense | 1.3B | 1.2B | 532.3M | 404.0M | 372.9M |
| Selling & Marketing Expense | 398.4M | 124.0M | 476.7M | 488.4M | 450.3M |
| Other Expenses | (411.6M) | (248.0M) | 33.3M | 62.2M | (40.8M) |
| Total Operating Expenses | 2.3B | 2.0B | 1.8B | 1.7B | 1.4B |
| Cost and Expenses | 3.1B | 2.7B | 2.4B | 2.2B | 1.9B |
| Operating Income (EBIT) | 273.3M | 533.5M | 484.2M | 185.8M | 161.0M |
| Non-Operating | |||||
| Interest Income | 70.1M | 74.9M | 74.9M | 58.3M | 18.0M |
| Interest Expense | 83.6M | 10.9M | 12.7M | 17.3M | 16.0M |
| Net Interest Income | (13.5M) | 64.0M | 62.2M | 41.0M | 2.1M |
| Other Non-Op Income/Expense | (124.1M) | (51.0M) | 57.5M | 2.8M | (11.4M) |
| Non-Operating Income (excl Interest) | 40.6M | 40.1M | (69.9M) | (16.6M) | (2.4M) |
| EBT (Pre-Tax Income) | 149.1M | 482.5M | 541.8M | 188.6M | 149.6M |
| Income Tax Expense | 76.1M | 133.6M | 114.9M | 20.9M | 8.0M |
| Bottom Line | |||||
| Net Income | 73.0M | 348.9M | 426.9M | 167.6M | 141.6M |
| Earnings from Cont. Ops | 73.0M | 348.9M | 426.9M | 167.6M | 141.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 69.3M | 348.9M | 434.2M | 167.6M | 141.6M |
| Per Share | |||||
| Basic EPS | $0.38 | $1.82 | $2.25 | $0.89 | $0.76 |
| Diluted EPS | $0.39 | $1.80 | $2.21 | $0.88 | $0.75 |
| Revenue Per Share | $17.65 | $16.80 | $15.02 | $12.88 | $11.31 |
| Shares | |||||
| Basic Shares Outstanding | 193.0M | 191.8M | 190.0M | 187.8M | 185.3M |
| Diluted Shares Outstanding | 194.1M | 197.4M | 196.7M | 191.6M | 189.0M |
| Profitability Metrics | |||||
| EBITDA | 385.7M | 572.9M | 650.5M | 306.8M | 265.4M |
| D&A | 153.0M | 79.6M | 96.4M | 104.4M | 102.0M |
| EBIT | 232.7M | 493.4M | 554.1M | 202.4M | 163.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026